Surface Oncology, Inc. (SURF)

Market Cap	46.52M
Revenue (ttm)	n/a
Net Income (ttm)	-89.53M
Shares Out	60.72M
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,173
Open	0.764
Previous Close	0.762
Day's Range	0.740 - 0.796
52-Week Range	0.555 - 2.150
Beta	1.68
Analysts	Strong Buy
Price Target	4.50 (+487.31%)
Earnings Date	Aug 2, 2023

About SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 19, 2018
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: SURF

Financial Performance

In 2022, SURF's revenue was $30.00 million, an increase of 1016.49% compared to the previous year's $2.69 million. Losses were -$63.59 million, -18.98% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 487.31% from the latest price.

Price Target

$4.5

(487.31% upside)

Analyst Consensus: Strong Buy